Novanta (NASDAQ: NOVT) reported Q1 EPS of $0.51, $0.19 better than the analyst estimate of $0.32. Revenue for the quarter came in at $155.5 million versus the consensus estimate of $142.61 million.

“We are pleased with the company’s performance in the first quarter, especially considering the significant challenges caused by the COVID-19 pandemic. In the first quarter, we delivered above our guidance for revenue, Adjusted EBITDA, and Adjusted EPS, and I am very proud of how our employees have stepped up and pulled together in the face of adversity,” said Matthijs Glastra, Chief Executive Officer of Novanta. “Our most important concern is the health and well-being of our employees, and we have taken swift actions to ensure their safety. Around the world, all of our factories continue to operate, delivering essential products to our customers who serve medical end markets. We have taken decisive actions to protect our employees, our operations, and our financial position, to help weather the current downturn, and emerge strong when the global economy begins to recover.”

For earnings history and earnings-related data on Novanta (NOVT) click here.